InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 -0.001 (-12.50%)+
Announcement
Release
25 May 2026 8:17AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, an Australian biotechnology company focusing on immunotherapies for solid cancers, announced the engagement of Dark Horse Consulting Group, a specialist in cell and gene therapy development, to assist in regulatory engagements with the US FDA for their CAR-T therapy, BZDS1901. This collaboration aims to ensure alignment with FDA expectations for manufacturing, preclinical, and clinical processes to facilitate upcoming Australian Phase 1 clinical trials. The partnership is expected to help AdAlta leverage potential expedited regulatory pathways that may enhance the therapy's value in treating rare cancers, such as mesothelioma. AdAlta's strategic move to involve Dark Horse Consulting underscores their commitment to optimizing the development and regulatory approval processes for BZDS1901, thereby bolstering their presence in the cellular immunotherapy market.
Key Points
  • AdAlta Limited engages Dark Horse Consulting for FDA regulatory engagement.
  • Focus on BZDS1901 CAR-T therapy for solid cancers, including mesothelioma.
  • Preparation for FDA pre-IND meeting to align manufacturing and trial design.
  • Potential for expedited regulatory pathways to enhance product value.
  • Strategic alignment with FDA expectations to support Australian clinical trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.